Aspira Women's Health raises ~$1.5M in private placement of common stock and warrants

Aspira Women's Health Inc.

Issued 3.3M shares and warrants to purchase up to 4.455M shares at $0.45 per unit.
Gross proceeds of approximately $1.485 million; warrants exercisable at $0.75 for 3 years.
Net proceeds to be used for working capital and general corporate purposes.
Closing occurred on June 5, 2026; sold to accredited and institutional investors.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aspira Women's Health Inc. entered into Purchase Agreement with accredited and institutional investors valued at approximately $1.485 million (effective 2026-06-05).

Action: entry
Agreement: equity purchase
Counterparty: accredited and institutional investors
Value: approximately $1.485 million
Effective: 2026-06-05

Exact text from the filing

On June 5, 2026, Aspira Women’s Healthcare Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreement”) with accredited and institutional investors (“the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of (i) 3,300,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”) and (ii) warrants (the “Common Warrants”) to purchase up to 4,455,000 shares of the Company’s Common Stock, at a purchase price of $0.45 per share of Common Stock and accompanying warrants.

View on SEC.gov

745 material agreements filed in the last 30 days. Browse all material agreements →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-26-000042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.